🔎 Trials Near Me

Utama › Leukemia Mieloid Akut › Arkansas

Kajian klinikal Leukemia Mieloid Akut di Arkansas

13 kajian untuk Leukemia Mieloid Akut sedang mencari peserta di lokasi di Arkansas.

Bandar di Arkansas

Teks kajian rasmi (Bahasa Inggeris)

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

  • Mercy Hospital Fort Smith, Fort Smith
  • CARTI Cancer Center, Little Rock
Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
Umur 40 hingga 75 · Semua jantina · Dikemas kini 2 Okt 2026 · NCT05334069

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

  • University of Arkansas for Medical Sciences, Little Rock
Mengambil pesertaFasa 2
Umur 18 hingga 59 · Semua jantina · Dikemas kini 28 Sep 2026 · NCT05554393

A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

  • University of Arkansas at Little Rock, Little Rock
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 25 Sep 2026 · NCT06852222

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

  • University of Arkansas for Medical Sciences, Little Rock
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 25 Sep 2026 · NCT05564390

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

  • University of Arkansas for Medical Sciences, Little Rock
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 22 Sep 2026 · NCT06317649

Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)

  • University of Arkansas for Medical Sciences, Little Rock
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 22 Sep 2026 · NCT06672146

Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)

  • University of Arkansas for Medical Sciences, Little Rock
Mengambil pesertaFasa 2
Umur 18 hingga 59 · Semua jantina · Dikemas kini 22 Sep 2026 · NCT05554406

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

  • Arkansas Children's Hospital, Little Rock
Mengambil pesertaFasa 3
6 Months – 21 Years · Semua jantina · Dikemas kini 17 Sep 2026 · NCT04293562

Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia

  • Arkansas Children's Hospital, Little Rock
Mengambil pesertaFasa 3
Umur 1 hingga 25 · Semua jantina · Dikemas kini 4 Sep 2026 · NCT07022678

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

  • Arkansas Children's Hospital, Little Rock
Mengambil pesertaFasa 1/2
Sehingga umur 22 · Semua jantina · Dikemas kini 25 Ogo 2026 · NCT04726241

Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)

  • Arkansas Children's Hospital, Little Rock
Mengambil pesertaFasa 3
29 Days – 21 Years · Semua jantina · Dikemas kini 24 Ogo 2026 · NCT05183035

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

  • Arkansas Children's Hospital, Little Rock
Mengambil pesertaKajian pemerhatian
Semua umur · Semua jantina · Dikemas kini 6 Jul 2026 · NCT01351545

Study of Talazoparib in Combination With Chemotherapy in Relapsed Pediatric AML to Determine Safety and Efficacy

  • Arkansas Children's Hospital, Little Rock
Mengambil pesertaFasa 1
Sehingga umur 21 · Semua jantina · Dikemas kini 22 Apr 2026 · NCT05101551

Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.